Darlene Noci, serving as the Chief Development Officer for Nuvalent, Inc. (NASDAQ:NUVL), has completed a substantial divestment of company equity. On July 1, 2026, Noci sold 23,000 shares of Nuvalent Class A Common Stock, realizing proceeds of approximately $2.84 million. The transaction was executed through a series of sales within a narrow price band, ranging from $123.51 to $123.62 per share, resulting in a weighted average sale price of $123.59. This activity occurred while the stock was trading in close proximity to its 52-week high of $123.80, a level reached following a robust 54% return over the previous year.
According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value. Investors can access detailed valuation metrics and 13 additional ProTips through the comprehensive Pro Research Report available for NUVL. The transaction details reveal that prior to the sale, Noci acquired the 23,000 shares through the exercise of stock options, with a total value of approximately $1.18 million. This acquisition included 9,146 shares obtained at $18.93 per share and 13,854 shares acquired at $72.35 per share. The shares from the first option were fully vested, while the shares from the second option are subject to a vesting schedule over four years from January 5, 2024, in equal monthly installments, contingent on continued service to Nuvalent.
Both the option exercises and the subsequent sale were executed under a Rule 10b5-1 trading plan that Noci adopted on November 18, 2024. Following these transactions, Darlene Noci directly holds 58,117 shares of Nuvalent Class A Common Stock. This executive activity coincides with significant corporate developments, including GSK's announcement of a $10.6 billion agreement to acquire Nuvalent. The acquisition includes a tender offer for all outstanding shares at $124 per share, representing a 40% premium to Nuvalent’s last closing price. This deal brings GSK two late-stage drug candidates, zidesamtinib and neladalkib, both under FDA review, as well as a third asset, NVL-330, in early trials.
Following the acquisition announcement, market sentiment shifted among analysts. Bernstein downgraded Nuvalent’s stock rating to Market Perform from Outperform and adjusted its price target to $124. Similarly, UBS downgraded Nuvalent to Neutral from Buy, aligning its price target to $124. On the other hand, Bernstein had previously reiterated an Outperform rating with a $172 price target prior to the acquisition announcement. Leerink also maintained an Outperform rating with a $165 price target after reviewing data presented at the ASCO conference. These developments provide a comprehensive view of Nuvalent’s current standing and future prospects amidst the acquisition by GSK. Nuvalent Follow Analyze NUVL Included in our AI-picked strategies Review strategies 123.72 ▼-0.01(-0.01%) Closed · 15:59:59 · USD 123.72 0.00(0.00%) After Hours · 16:25:04 1D 1W 1M 6M 1Y 5Y Max Created with Highcharts 11.4.8 14:00 15:00 16:00 17:00 18:00 19:00 123.65 123.71 123.75 Analyze NUVL This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Is now the time to buy NUVL? ProPicks AI evaluates NUVL every month against thousands of alternatives using 100+ financial metrics. It found Siemens Energy (+231.5%) and Sandisk (+189%) before the crowd did. Could NUVL be next—or is there a better opportunity in the same space? Don't wait to find out. July Sale - 60% Off InvestingPro